Paclitaxel polymer implant

Drug Profile

Paclitaxel polymer implant

Latest Information Update: 01 Jun 2007

Price : $50

At a glance

  • Originator Bioxel Pharma; PolyGene
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 01 Jun 2007 Preclinical development is ongoing
  • 28 Mar 2002 Preclinical trials in Solid tumours in Israel (Intratumoural)
  • 28 Mar 2002 Preclinical trials in Solid tumours in Canada (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top